Pörssitiedote

Nightingale Health strengthens its commercial operations with new EMEA appointment

Nightingale Health Plc | Stock Exchange Release | June 13, 2025 at 11:50:00 EEST

As part of its ambition to strengthen regional commercial activities, Nightingale Health (Nasdaq Helsinki: HEALTH; OTCQX: NHLTY, NGHLF) has appointed Minja Salmio, currently Chief Legal Officer and a key member of Nightingale Health’s management team, as Chief Commercial Officer for the EMEA region.

Nightingale Health’s commercial operations are structured around three regions: Asia-Pacific (APAC); Europe, the Middle East and Africa (EMEA); and the Americas. The commercial operations in APAC are led by Satu Saksman, while CEO Teemu Suna continues to lead the business in the Americas for the time being. In her new role, Minja Salmio will be responsible for the EMEA region.

“Minja has a broad understanding of the company and as CLO she has already played a key role in our commercial operations. This experience makes her transition into a commercial leadership role a natural progression, especially given our ambition to further expand our commercial activities,” says Teemu Suna, CEO and Founder of Nightingale Health.

In addition to this appointment, Satu Sirén-Lähdeaho, currently Head of Legal, will step into the role of General Counsel. Over her many years at the company, she has been instrumental in the company’s Legal and Compliance function and supporting critical business initiatives.

The new appointments will take effect from 13 June 2025.

Nightingale Health’s Management Team as of 13 June 2025:

Teemu Suna, CEO, Founder
Antti Kangas, CTO, Founder
Satu Saksman, CCO, APAC, Co-founder
Minja Salmio, CCO, EMEA
Salla Ruosaari, Chief R&D Officer
Jeffrey Barrett, CSO
Tuukka Paavola, CFO
Janna Ranta, COO

About Nightingale Health
Nightingale Health has developed the world's most advanced health check. Our solution provides risk detection for multiple chronic diseases from a single blood sample. Nightingale Health Check can be scaled to entire populations and it can replace many of the current routine disease risk assessments and health screening programs for chronic diseases. Detecting disease risks comprehensively and efficiently allows effective targeting and tracking of health interventions, and better prevention of chronic diseases. Nightingale Health's mission is to build sustainable healthcare and reduce health inequalities. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and eight subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The Company's technology is being used in many of the world's leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company's Series B shares are listed on the Main Market of Nasdaq Helsinki and on the OTCQX International market. Read more: https://nightingalehealth.com/